相关实验视频

Updated: May 7, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

在胃癌中进行代性腹腔内化学疗法腹腔内癌症 (Peritoneal Carcinomatosis)

Fatemeh Tajik¹, Belain Eyob², Aaqil M Khan¹

¹Department of Surgery, University of California Irvine Medical Center, Orange, CA 92868, USA.

|January 25, 2025

概括

腹腔内化学疗法 (IP) 通过将药物直接输送到腹膜,提供了改善的胃癌腹膜转移治疗. 将IP化疗与全身疗法和手术相结合可能会显著改善患者的生存结果.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

转移性胃癌 (GC) 与腹癌 (PC) 尽管有系统治疗,但结果不佳.
血液-腹膜屏障限制了GC腹膜转移中的全身药物透.
腹腔内 (IP) 化疗是一种有希望的策略,可以克服这些局限性.

研究的目的:

为了审查胃癌腹转移的生物学.
为了评估双向代IP化疗在GC与PC的证据.
探索IP化疗在增强手术切除和生存中的作用.

主要方法:

在主要数据库 (PubMed,Scopus,Embase,Web of Science,Google Scholar) 中进行全面的文献搜索.
包括正在进行的II/III期临床试验,用于PC的GC的代IP化疗.
对IP化疗的生物机制和药物动力学优势的审查.

主要成果:

IP化疗允许高度的药物直接进入腹腔,减少全身毒性并提高疗效.
像HIPEC,PIPAC和NIPEC这样的方法进一步优化了IP化疗的提供.
代性IP化疗与全身疗法相结合,对患有腹膜转移的患者显示出显著的生存益处.

结论:

IP化疗对于治疗胃癌症至关重要,特别是在选定的患者中进行细胞还原性手术.
结合系统和区域IP化疗控制,改善了手术切除率.
这种综合性方法为患有晚期胃癌和腹膜扩散的患者提供了显著的生存益处.

关键词:

细胞还原性手术 (CRS)胃癌胃癌是一种胃癌.加热的腹膜内化学疗法 (HIPEC)腹膜内 (IP) 化疗的化学疗法正常热内皮层化学疗法 (NIPEC)腹腔内皮癌的发生在压力下进行腹膜内空气化疗 (PIPAC).

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...